LAPTM4B polymorphism increases susceptibility to multiple cancers in Chinese populations: a meta-analysis

BMC Genetics

Shan Li¹  Xue Qin¹  Qiliu Peng¹  Yu He¹  Taijie Li¹  Li Xie¹  Jian Wang¹  Yan Deng¹  Yu Lu¹  Cuiju Mo¹ 

[1] Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China

关键词: Meta-analysis;    Cancer;    Polymorphism;    LAPTM4B;   

Others  :  866544
DOI  :  10.1186/1471-2156-15-48

 received in 2014-01-05, accepted in 2014-04-10,  发布年份 2014

【 摘 要 】

Background

Lysosome-associated protein transmembrane-4 beta (LAPTM4B) is a novel cancer-related gene. While recent studies have reported that the LAPTM4B polymorphism increased the susceptibility of several cancers, the results remain inconclusive. Therefore, we performed a meta-analysis to systematically summarize the possible association.

Results

The meta-analysis was conducted based on 17 studies in Chinese populations, including 4160 cases and 4148 controls. The relevant studies were searched through electronic databases updated in November 2013. The strength of association between the LAPTM4B polymorphism and susceptibility to multiple cancers was assessed by odds ratio (OR) and 95% confidence interval (95% CI).

The meta-analysis results suggested that the LAPTM4B polymorphism was significantly associated with overall susceptibility to multiple cancers in all genetic models (*2 vs. *1, OR = 1.53, 95% CI = 1.37–1.70; *2/2 vs. *1/1, OR = 2.18, 95% CI = 1.72–2.75; *2/1 vs.*1/1, OR = 1.62, 95% CI = 1.41–1.86; *2/1 + *2/2 vs. *1/1, OR = 1.70, 95% CI = 1.47–1.97; *2/2 vs. *2/1 + *1/1, OR = 1.76, 95% CI = 1.50–2.05). Further subgroup analysis revealed a significant association between the LAPTM4B polymorphism and cancer susceptibility in the subgroups stratified by control source, cancer type, histopathologic differentiation, and TNM stage.

Conclusions

This meta-analysis indicated that the LAPTM4B *2 allele was associated with increasing risk of multiple cancers, tumor initiation and development.

【 授权许可】

   
2014 Mo et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Bredberg A: Cancer: more of polygenic disease and less of multiple mutations? A quantitative viewpoint. Cancer 2011, 117(3):440-445.
• [2]Zhang J, Liu J, Han Y, Zhang N, Rui J, Jin C, Zhou R: Screening of novel hepatocellular carcinomaassociated genes. J Beijing Med Univ 2001, 33(1):54-57.
• [3]Liu JJ, Zhang J, Zhang N: Identification of new hepatocellular carcinoma related genes by fluorescent differential display. J Beijing Med Univ 2000, 32(5):411-414.
• [4]Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X, Ye DX: Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003, 22(32):5060-5069.
• [5]Liu J, Zhou R, Zhang N, Rui J, Jin C: Biological function of a novel gene overexpressed in human hepatocellular carcinoma. Chin Med J (Engl) 2000, 113(10):881-885.
• [6]Peng C, Zhou RL, Shao GZ, Rui JA, Wang SB, Lin M, Zhang S, Gao ZF: Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J Gastroenterol 2005, 11(18):2704-2708.
• [7]Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC: Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010, 16(2):214-218.
• [8]Zhang G, Liang Y, Huang Y, Chen Y, Zhou R: Elevated lysosome-associated protein transmembrane-4beta-35 is an independent prognostic marker in pancreatic carcinoma. J Int Med Res 2012, 40(4):1275-1283.
• [9]Zhou L, He XD, Yu JC, Zhou RL, Yang H, Qu Q, Rui JA: Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg 2010, 199(4):515-521.
• [10]Zhou L, He XD, Yu JC, Zhou RL, Xiong FX, Qu Q, Rui JA: Expression of LAPTM4B in gallbladder carcinoma cells: the role in invasive potential. Hepatogastroenterology 2010, 57(98):207-211.
• [11]Liu X, Zhou R, Zhang Q, Zhang Y, Shao G, Jin Y, Zhang S, Lin M, Rui J, Ye D: [Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene]. Beijing Da Xue Xue Bao 2003, 35(4):340-347.
• [12]Yang H, Zhai G, Ji X, Xiong F, Su J, McNutt MA: LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma. PLoS One 2012, 7(4):e34984.
• [13]Zhai G, Yan K, Ji X, Xu W, Yang J, Xiong F, Su J, McNutt MA, Yang H: LAPTM4B allele *2 is a marker of poor prognosis for gallbladder carcinoma. PLoS One 2012, 7(9):e45290.
• [14]Yang Y, Ge L: Association of LAPTM4B gene polymorphism with human tumors. Pract Oncol 2013, 27(2):172-176.
• [15]Sun G, Li Z, Hao W, Niu J, Yin J, Yan Y: Relationship between lysosome-associated protein transmembrane4β polymorphism and Susceptmmty to liver cancer. World Chin J Digestology 2008, 16(8):908-911.
• [16]Qi R, Shi X: LAPTM4B gene polymorphism and liver cancer susceptibility (postgraduate’s thesis). 2010.
• [17]Zhai G, Yang H, Ji X, Xiong F, Su J, McNutt MA, Li X: Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients. Med Oncol 2012, 29(4):2744-2749.
• [18]Wang S, Zhang QY, Zhou RL: Relationship between LAPTM4B gene polymorphism and susceptibility of primary liver cancer. Ann Oncol 2012, 23(7):1864-1869.
• [19]Deng LJ, Zhang QY, Liu B, Zhou RL: [Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer]. Beijing Da Xue Xue Bao 2005, 37(3):302-305.
• [20]Li C, Zhou Q, Wang Y, Chen X, Yang X, Zhu D: [Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer]. Zhongguo Fei Ai Za Zhi 2006, 9(2):109-112.
• [21]Fan M, Liu Y, Zhou R, Zhang Q: Association of LAPTM4B gene polymorphism with breast cancer susceptibility. Cancer Epidemiol 2012, 36(4):364-368.
• [22]Li X, Kong X, Chen X, Zhang N, Jiang L, Ma T, Yang Q: LAPTM4B allele *2 is associated with breast cancer susceptibility and prognosis. PLoS One 2012, 7(9):e44916.
• [23]Meng F, Song H, Luo C, Yin M, Xu Y, Liu H, Zhou R, Lou G: Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer 2011, 117(12):2652-2658.
• [24]Cheng XJ, Xu W, Zhang QY, Zhou RL: Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol 2008, 19(3):527-532.
• [25]Yang H, Zhai G, Ji X, Xiong F, Su J, McNutt MA: Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients. Med Oncol 2012, 29(4):2809-2813.
• [26]Liu Y, Zhang QY, Qian N, Zhou RL: Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol 2007, 18(2):311-316.
• [27]Wang B, Xu J, Zhou R, Zhang Q: Association of LAPTM4B gene polymorphism with nasopharyngeal carcinoma susceptibility in a Chinese population. Med Oncol 2013, 30(1):470.
• [28]Xu Y, Liu Y, Zhou R, Meng F, Gao Y, Yang S, Li X, Yang M, Lou G: LAPTM4B polymorphisms is associated with ovarian cancer susceptibility and its prognosis. Jpn J Clin Oncol 2012, 42(5):413-419.
• [29]Wang S, Zhang Q: Association of lysosome associated protein transmembrane 4 beta gene polymorphism with the risk of pancreatic cancer. Chin J Cancer Res 2010, 22(4):291-295.
• [30]Sun L, Zhang Q, Liu Y, Qian N: Relationship between Human Novel Gene LAPTM4B gene polymorphism and susceptibility of Lymphoma. Cancer Res Prev Treat 2007, 34(4):245-248.
• [31]Meng F, Li H, Zhou R, Luo C, Hu Y, Lou G: LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis. Biomarkers 2013, 18(2):136-143.
• [32]Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003, 33(2):177-182.
• [33]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
• [34]Kasper G, Vogel A, Klaman I, Grone J, Petersen I, Weber B, Castanos-Velez E, Staub E, Mennerich D: The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 2005, 224(1):93-103.
• [35]He J, Shao G, Zhou R: [Effects of the novel gene, LAPTM4B, highly expression in hepatocellular carcinoma on cell proliferation and tumorigenesis of NIH3T3 cells]. Beijing Da Xue Xue Bao 2003, 35(4):348-352.
• [36]Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, Pang Y, Shan Y, Xiong FX, Shao GZ, Zhou RL: LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 2010, 29(43):5785-5795.
• [37]Liu X, Xiong F, Wei X, Yang H, Zhou R: LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci 2009, 100(12):2335-2340.